U.S. Metals and Mining Stock News

Public Storage recently moved into the spotlight ahead of its fiscal fourth-quarter 2025 earnings release, as analysts anticipated a marginal uptick in funds-from-operations per share despite softer industry conditions and higher operating costs. Investor attention has also been drawn to the REIT’s portfolio expansion, including about US$1.10 billions in acquisitions and development alongside successful lease-up of newer properties, which could influence expectations for its long-term...

Recent insider stock sales by top executives at Protagonist Therapeutics (PTGX), including the CEO, President, CMO, and CFO, have drawn fresh attention, especially with no recent insider buying reported. See our latest analysis for Protagonist Therapeutics. Those insider sales come after a huge multi year run, with the 1 year total shareholder return at about 120% and the 3 year total shareholder return more than 5x, even though the 30 day share price return shows a 6.4% pullback and the...

Why Remitly’s latest growth figures are getting fresh attention Recent commentary around Remitly Global (RELY) centers on its 25% year over year revenue growth and 35% send volume increase to US$19.5b, as well as growing interest in its profitability path and trading activity. See our latest analysis for Remitly Global. The latest 1-day share price return of 0.77% and 90-day share price return of 16.4% decline, against a 1-year total shareholder return of 38.44% decline and 3-year total...

Acuity Inc.’s Board of Directors recently approved a 17% increase in the quarterly dividend to US$0.20 per share, payable on February 13, 2026, to shareholders of record as of February 2, 2026. This higher payout underlines the company’s emphasis on returning cash to investors through regular income, complementing its industrial technology and intelligent building solutions focus. Next, we’ll examine how this dividend increase shapes Acuity’s investment narrative, particularly its appeal to...

Cohen & Steers, Inc. reported past fourth-quarter 2025 results, with revenue rising to US$143.8 million while net income and earnings per share from continuing operations declined year on year. Alongside the earnings, the firm highlighted continued positive investment flows, a strong institutional pipeline, and appointed Diana Shieh to lead and scale its private real estate asset management platform. Next, we examine how these developments, particularly the expanding institutional pipeline,...

TechnipFMC (FTI) is back in focus after the board approved a roughly US$2.00b share repurchase program and the company reported fresh subsea and iEPCI contract awards with bp, Eni, and Chevron. See our latest analysis for TechnipFMC. At a share price of US$54.26, TechnipFMC has seen a 21.52% 1 month share price return and a 33.91% 3 month share price return. Its 1 year total shareholder return of 73.89% and very large 5 year total shareholder return highlight momentum that recent contract...

In January 2026, a consortium led by Amentum won a framework contract worth up to US$207 million to provide program management and technical solutions for planning and developing up to two gigawatt-scale nuclear power plants in the Netherlands, while Amentum was also selected as program delivery partner for early Rolls-Royce SMR deployments in the UK and Czech Republic. Together, these projects highlight Amentum’s expanding role across both large conventional nuclear builds and emerging SMR...

Why Kerrisdale’s short report and the bank application matter for Affirm Kerrisdale Capital’s recent short report on Affirm Holdings (AFRM), paired with the company’s application to launch an FDIC insured industrial loan company, has put the stock’s credit profile and long term funding model squarely in focus. See our latest analysis for Affirm Holdings. Those headlines have landed against a choppy backdrop, with a 1 day share price return of 1.93% decline and a 30 day share price return of...

Why RH (RH) Is Back On Watch For Investors RH (RH) has recently drawn fresh attention after a sharp move in its share price, with the stock up around 23% over the past month and roughly 21% in the past 3 months. That price action stands in contrast to a total return decline of about 45% over the past year and weaker multi year returns. This has prompted investors to reassess how the company’s current fundamentals and valuation line up with expectations. See our latest analysis for RH. Even...

Earlier in January 2026, Skyward Specialty Insurance Group, Inc. expanded its E&S Property offering by adding Excess coverage aimed at technically complex, non-catastrophe property risks and layered programs. This move, aligned with the carrier’s “Rule Our Niche” focus and recent leadership changes in Inland Marine and Transactional E&S, underscores its effort to address areas where traditional insurance markets fall short. Next, we’ll examine how the added Excess E&S Property capacity...

What sparked the latest move in ServisFirst Bancshares (SFBS)? ServisFirst Bancshares (SFBS) shares moved sharply after fourth quarter 2025 earnings topped revenue and profit forecasts, with management pointing to loan growth, wider net interest margins, tighter costs, and a higher dividend. See our latest analysis for ServisFirst Bancshares. The recent earnings jump and dividend increase came after a period where the share price has been firming, with a 30 day share price return of 11.41%...

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough...

Sterling Infrastructure’s E-Infrastructure segment, which includes data center construction, has recently been highlighted as the key engine of the business, with commentary emphasizing its strong underlying fundamentals and connection to AI-related capacity needs. An interesting insight is that some analysts view data center and AI infrastructure demand as sufficiently durable to counter concerns about an AI spending bubble, placing this segment at the heart of Sterling Infrastructure’s...

EMBARK readout puts ELEVIDYS back in focus Sarepta Therapeutics (SRPT) is back on investor radars after the company scheduled a January 26 webcast to share 3 year topline functional outcomes from the EMBARK Phase 3 ELEVIDYS trial in Duchenne muscular dystrophy. See our latest analysis for Sarepta Therapeutics. At a share price of US$21.13, Sarepta’s recent performance has been weak, with a 30 day share price return of 4.5% decline and a 1 year total shareholder return of 81.9% loss. This...

Why the Savara (SVRA) story is back in focus The latest headline around Savara (SVRA) centers on a law firm investigation into potential fiduciary duty breaches, following a class action tied to the FDA’s refusal of the company’s MOLBREEVI Biologics License Application. See our latest analysis for Savara. The legal scrutiny arrives after a sharp reaction to the FDA’s MOLBREEVI decision. At the same time, the stock’s 90 day share price return of 37.44% and 1 year total shareholder return of...

Why Erasca’s latest equity raise matters for current and prospective shareholders Erasca (ERAS) has closed an upsized follow on equity offering, raising about US$225 million by selling 22,500,000 common shares at US$10.00, a move that directly affects existing and future shareholders. See our latest analysis for Erasca. The equity raise comes after a sharp re-rating in the stock, with a 30 day share price return of 186.21% and a year to date share price return of 177.44%. The 1 year total...

Why V2X is back on investor radars V2X (VVX) has drawn fresh attention after advancing to Phase II of the US Army's Flight School Next competition and securing a role under the Missile Defense Agency's SHIELD contract vehicle. See our latest analysis for V2X. The SHIELD award and Flight School Next progress come as momentum in the shares has picked up, with a 25.4% 1 month share price return and a 25.8% year to date share price return, alongside a 1 year total shareholder return of 31.6%. If...

Advance Auto Parts (AAP) is back in focus after Northcoast Research shifted its view on the stock, citing early progress in CEO Shane O’Kelly’s turnaround, which is built around store closures and revamped distribution. See our latest analysis for Advance Auto Parts. The recent Northcoast upgrade comes after a volatile stretch for the stock, with a 13.38% 1 month share price return and a 20.26% year to date share price return, but a 66.07% 3 year total shareholder return decline that still...

National HealthCare Corporation recently reached a record high level after reporting 22.67% revenue growth over the past year and declaring a US$0.64 quarterly dividend per share, underscoring its focus on returning cash to shareholders. The company’s ‘GREAT’ financial health score, combined with strong recent results and ongoing dividend payments, may be reinforcing investor confidence in its operational resilience. We’ll now examine how National HealthCare’s robust revenue growth and...

Terreno Realty (TRNO) reported the completion and stabilization of Countyline Corporate Park Phase IV Building 32 in Hialeah, Florida, a 164,000 square foot industrial distribution asset that is already fully leased. See our latest analysis for Terreno Realty. The latest completion at Countyline comes as Terreno Realty’s share price has a 30-day share price return of 3.7% and a year to date share price return of 5.91%. The 5-year total shareholder return of 26.75% points to steadier long term...

In recent months, analysts have become more positive on The RealReal after the company reported past third-quarter results that outpaced forecasts for revenue and adjusted EBITDA. Alongside this, The RealReal’s introduction of its Athena AI system to support authentication, descriptions, and pricing underscores a push toward greater efficiency in its luxury resale operations. Next, we’ll explore how this combination of analyst confidence and Athena-driven operational enhancement shapes The...

Earlier this week, analysts at KeyBanc and Canaccord issued upbeat research on LifeStance Health Group, highlighting strengthening business momentum and supportive payer policies that expand in-network access to behavioral healthcare. Their commentary underscores how LifeStance’s position within a changing healthcare landscape may benefit from insurers’ efforts to widen access to mental health services. We’ll now examine how this increased analyst optimism around payer support and access to...

In recent days, QuidelOrtho has faced renewed scrutiny over its financial position, with analyses pointing to negative earnings, shrinking margins, a low interest coverage ratio and an Altman Z-Score of 0.2 that places the diagnostics group in the distress zone. Alongside these concerns, the company has highlighted its role in blood-supply resilience and plans to report fourth-quarter and full-year 2025 results on February 11, 2026, underscoring a contrast between operational initiatives and...

In its latest reported quarter, ESCO Technologies delivered an 18.1% year-on-year revenue increase, significantly surpassing analyst expectations and pairing that with full-year EPS guidance that came in above prior forecasts. This combination of revenue outperformance and stronger-than-expected earnings guidance highlights improving operational momentum across ESCO’s aerospace, defense, and utility-focused businesses. We’ll now examine how ESCO Technologies’ stronger-than-expected full-year...